Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Wednesday, 23'rd Apr 2025
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
02:12pm, Tuesday, 22'nd Apr 2025
Ionis will announce its Q1 earnings on April 30th - in my view, the company is in a strong position and its current valuation of $4.5bn is far too low. The company recently secured approval for olezar
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
09:20am, Thursday, 10'th Apr 2025
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright
06:10am, Monday, 07'th Apr 2025
H.C. Wainwright initiated coverage of Ionis Pharmaceuticals with a Buy rating and $45 price target. Ionis is a commercial-stage biotech company focused on RNA-targeted therapeutics for a range of dise
Ionis to host expert panel discussion on sHTG
07:05am, Thursday, 03'rd Apr 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation
Ionis to present at upcoming investor conferences
07:05am, Monday, 31'st Mar 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24th Annual Need
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
09:35am, Thursday, 27'th Mar 2025
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
07:00am, Wednesday, 26'th Mar 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries out
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
12:36pm, Friday, 21'st Mar 2025
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
06:00pm, Tuesday, 11'th Mar 2025
CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
06:00pm, Tuesday, 11'th Mar 2025
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has entered into a license agreement with Ionis
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the tr
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 25'th Feb 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
12:15pm, Thursday, 20'th Feb 2025
IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.
